Gilead Sciences Gains FDA Approval for Hepcludex as First Chronic HDV Treatment

Gilead Sciences' Hepcludex (bulevirtide-gmod) injection now carries an FDA-approved indication for chronic hepatitis delta virus (HDV) infection, and with it, a boxed warning on discontinuation risks that will demand close attention from QA directors and regulatory affairs leads managing post-market labeling and pharmacovigilance obligations. The May 22, 2026 approval marks the first time any therapy has cleared the FDA for this indication.

Hepcludex was approved under the Accelerated Approval pathway, supported by Breakthrough Therapy and Orphan-Drug Designations alongside Priority Review. The pivotal data came from Trial MYR301, a multi-center, randomized, open-label, parallel-arm Phase 3 study. At week 48, 48% of patients in the immediate-treatment arm achieved the combined primary endpoint, undetectable or significantly reduced HDV RNA plus ALT normalization, versus 2% in the delayed-treatment group. Undetectable HDV RNA rates climbed to 50% by week 144 in the treatment arm, providing the durability signal that underpinned the submission.

For regulatory teams, the Accelerated Approval designation introduces a defined post-market commitment landscape. Confirmatory trial data will be required to verify and describe clinical benefit, and any labeling updates tied to those outcomes will need to move through change-control processes aligned with 21 CFR Part 314 supplement requirements. The boxed warning, specifying that abrupt discontinuation may trigger severe acute exacerbations of both HDV and HBV, adds a layer of labeling compliance scrutiny that extends to patient-facing materials, risk communication, and any future lifecycle management submissions.

On the manufacturing side, Hepcludex is an injectable biologic, a dosage form where sterility assurance, container-closure integrity, and cold-chain controls sit at the center of GMP compliance. Plant heads overseeing fill-finish or secondary packaging operations for similar injectable biologics should read this approval as a signal that FDA is prepared to move quickly on rare-disease biologics, and that the inspection readiness expectations for post-approval manufacturing changes will be correspondingly rigorous.

HDV infection occurs exclusively in patients co-infected with hepatitis B virus, a population that has historically had no approved antiviral option specifically targeting the delta virus. The approved dose is 8.5 mg once daily by subcutaneous injection, with a safety profile that includes hypersensitivity reactions up to anaphylaxis, injection site reactions, and pruritus.

The confirmatory trial milestones required under Accelerated Approval will serve as the measurable checkpoint against which Gilead's post-market commitments, and the FDA's continued approval status for Hepcludex, will ultimately be assessed.

Source: U.S. Food and Drug Administration press release via FDA.gov, May 22, 2026.